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doi:10.1016/j.jtcvs.2007.05.031bjective: We investigated the clinical, surgical, and pathologic features of sarco-
atoid lung carcinomas with spindle/giant cells, giving special attention to the
rognostic behavior of these rare tumors.
ethods: Surgical specimens from 39 patients (29 men and 10 women; mean age,
1 years) were examined by means of light microscopy. Preoperative and postop-
rative data were collected, and survival was calculated by using the Kaplan–Meier
ethod.
esults: Nineteen patients were diagnosed with cancer preoperatively. Only one
arcomatoid tumor had been diagnosed. Presenting symptoms were noted in 85% of
atients, and complete resection was achieved in 37 tumors. Postoperative pTNM
taging: T2/T3/T4, 22/15/2; N0/N1/N2, 28/8/3; 15 stage IB, 14 stage IIB, 7 stage
IIA, 2 stage IIIB, and 1 stage IV. Histopathologic analysis revealed necrosis in 90%
f the tumors (34 pleomorphic, 3 spindle cell, and 2 giant cell carcinomas). During
ollow-up (median, 24 months), 21 patients died of disease recurrence, and 3 died
f postoperative complications. The 5-year survival rate (33%; median, 11 months)
as negatively influenced by large tumors (7.5% survival for7 cm vs 56% for7
m, P  .0026). The disease-free interval was significant for patients who relapsed
0% for disease-free interval 6 months vs 33% for disease-free interval 6
onths, P  .0019).
onclusions: A highly heterogeneous group, spindle/giant cell lung carcinomas tend
o be symptomatic, peripheral, and necrotic. Preoperative diagnosis is difficult. Most
atients in our study relapsed and died the first year after surgical intervention.
urgical intervention can permit long-term survival, but adjuvant therapy warrants
onsideration because of the aggressive nature of these tumors.
rimary lung cancer, a major public health problem in France, is the first cause
of death from cancer in men (23.5%) and the third cause in women (6.4%)
after breast and colorectal cancer.1 An estimated 28,000 new cases occurred
n 2000. The 5-year survival rate, all stages considered together, remains a low 13%
n men and 16% in women.2
During the last 2 decades, the histologic classification of lung cancer has
volved3-5 thanks to progress in histologic and immunohistochemical techniques
nd molecular biology. One newly defined entity is a heterogeneous group of
on–small cell lung carcinomas (NSCLCs) referred to as “carcinomas with pleo-
orphic, sarcomatoid, or sarcomatous elements” that contain a sarcoma or sarcoma-
ike component.4 Three groups are currently recognized: carcinomas with spindle
ells, giant cells, or both; carcinosarcomas; and pulmonary blastomas. Histopatho-
ogically, carcinomas with spindle cells, giant cells, or both are subdivided into 3
roups: (1) pleomorphic carcinoma, an NSCLC containing at least 10% spindle
ells, giant cells, or both or a carcinoma consisting of both spindle and giant cells;
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TS 2) spindle cell carcinoma (SCC) containing only spindle
ells; and (3) giant cell carcinoma (GCC) containing only
iant cells. These tumors feature a high mitotic count, and
arge zones of necrosis are commonly encountered.4 Anti-
odies against epithelial markers, such as cytokeratins and
pithelial membrane antigen or, more recently, monoclonal
ntibodies, are helpful in establishing the diagnosis.6
Several studies have investigated the histologic features
f these tumors,6-12 but they are all retrospective and cover
nly small numbers of patients. Little research has been
onducted on these tumors’ clinical, therapeutic, and prog-
ostic aspects.13-16
This study reports our findings concerning the clinical,
urgical, and pathologic features of these tumors and anal-
ses the outcome of sarcomatoid carcinomas with spindle
ells, giant cells, or both (SCSGCs).
aterials and Methods
rom January 1, 1991, to May 31, 2006, all patients with SCSGCs
een in our department who underwent anatomic resection and
ystematic lymph node dissection (interlobar, hilar, and mediasti-
al nodes) were included in the study. All pleomorphic carcino-
as, pure SSCs, and pure GCCs were included. Carcinosarcomas
nd pulmonary blastomas were excluded, as were specimens ob-
ained by means of atypical resections or other surgical biopsies.
ll tumor samples were reinterpreted by the same pathologist (S.
assalle). All of the tumors satisfied the criteria of the latest
nternational 2004 World Health Organization (WHO) classifica-
ion.5 Demographic data, clinical symptoms, and preoperative
ssessment data were recorded for all patients. The pretherapy
ork-up systematically included chest radiography, fiberoptic
ronchoscopy, and chest computed tomography (CT) with contrast
nhancement. Abdominal and brain CT scans, a bone scan, and,
tarting in 2003, an F-18 fluorodeoxyglucose positron emission
omographic (FDG-PET) scan completed the assessment. When
ecessary, diagnosis, staging, or both was supplemented by
ransparietal fine-needle biopsy and video-assisted mediastinos-
opy. Clinical disease staging was performed according to the
997 International TNM staging system.17 The operative tech-
iques, types of resection, postoperative complications, and hos-
ital stay were recorded, as was use of complementary therapy
Abbreviations and Acronyms
CT  computed tomography
DFI  disease-free interval
FDG-PET fluorodeoxyglucose positron emission
tomography
GCC  giant cell carcinoma
NSCLC  non–small cell lung carcinoma
SCSGC  sarcomatoid carcinoma with spindle cells,
giant cells, or both
SSC  spindle cell carcinoma
WHO World Health Organizationchemotherapy, radiotherapy, or both). The histologic features of r
20 The Journal of Thoracic and Cardiovascular Surgery ● Septehe tumors (size, location, necrosis, blood vessel invasion, and
TNM) were also noted.
Follow-up was complete for all patients, and their status was
nown as of June 15, 2006. Any relapse (local or distant), the
isease-free interval (DFI; time between surgical intervention and
elapse), and the duration of patient survival were noted. The
robability of survival and the various prognostic factors were
alculated according to the Kaplan–Meier method for univariate
nalysis and the Cox proportional hazards model for multivariate
nalysis. Statistical analysis was carried out with SPSS software
SPSS, Inc, Chicago, Ill).
esults
hirty-nine patients met the selection criteria, and the mean
ge was 61 years (range, 39–84 years). The patient’s char-
cteristics are listed in the Table 1. Chest radiographs re-
ealed an excavating lesion in 6 (15%) patients, and CT
canning demonstrated signs of necrosis in 27 (69%) pa-
ients. Nineteen patients had a preoperative diagnosis of
ung cancer, and only 1 was positive for sarcomatoid cancer.
ourteen patients had an F-18 FDG-PET scan: all tumors
howed intense enhancement (standardized uptake value
ange, 16–26).
Resections consisted of pneumonectomy in 7 cases (1
omplete), bilobectomy in 3 cases, and lobectomy in 29
ases. Associated procedures included 2 wedge resections
trans-fissural tumors), 6 parietal resections, and 1 diaphrag-
atic resection extending to the atrium. A complete R0
esection was achieved in 37 (95%) patients; 2 patients had
able 1. Patient characteristics
Patients
ex Male 29 (74%)
Female 10 (26%)
ymptoms Yes 33 (85%)
No 6 (15%)
ocation Left 15 (38%)
Right 24 (62%)
ize 7 cm 19 (49%)
7 cm 20 (51%)
istology Pleomorphic 34 (87%)
Pure spindle cells 2 (5%)
Pure giant cells 3 (8%)
T T2 22 (56%)
T3 15 (39%)
T4 2 (5%)
N N0 28 (72%)
N1 8 (20%)
N2 3 (8%)
tage IB 15 (39%)
IIB 14 (36%)
IIIA 7 (17%)
IIIB 2 (5%)
IV 1 (3%)esidual (R1) disease microscopically.
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G
TSMacroscopic analysis revealed that the tumors were
oorly circumscribed and contained hemorrhagic foci. Ne-
rosis was present in 35 (90%) tumors, and blood vessel
nvasion was present in 9 (23%) cases. According to histo-
ogic data (Table 1), 18 times the GCC component was
redominant, and 21 times the SCC component was
redominant.
Three patients died at 10, 12, and 28 postoperative days
f myocardial infarction, hemothorax, and upper digestive
emorrhage, respectively. There were 4 major complica-
ions (empyema, pneumonia, hemothorax, and small bowel
erforation) and 8 minor complications. The mean hospital
tay was 12 days (range, 7–46 days). Seventeen patients had
omplementary treatments: chemotherapy was administered
s induction therapy, adjuvant therapy, or both (alkylating
gent [cisplatin]  antimetabolite [gemcitabine] or spindle
oisons [vinorelbine or taxane]); radiotherapy was admin-
stered as adjuvant therapy.
Median follow-up was 24 months (range, 1–179
onths). Fifteen patients are still alive, but 3 had metastatic
ecurrences (brain, small bowel, and lung, respectively)
anaged by means of surgical intervention and chemother-
py. Twenty-four patients have died. Except for the 3 pa-
ients who died in the immediate postoperative period, the
thers all died of recurrent disease: local (10 cases), meta-
tatic (brain in 9, bone in 6, lung in 4, bowel in 2, and
uprarenal gland in 1), or both. The mean DFI was 4 months
range, 2–19 months).
The overall 5-year survival rate was 33% (median, 11
onths; Figure 1); it was poorer for tumors of 7 cm or larger
7.5%) than for tumors of less than 7 cm (56%; P  .0026;
igure 2). Twenty-four patients relapsed. The 5-year sur-
ival rate was also poorer when the DFI was less than 6
onths (0%; 18 patients) than when it was 6 months or
Figure 1. Overall survival.onger (33%; 6 patients; P  .0019; Figure 3). (
The Journal of ThoracicNonsignificant differences were noted for histology
49% GCC predominant vs 21% SCC predominant, P 
08), complementary treatments (51% with vs 21% without,
 .06), lymph node involvement (36% for N0 vs 24% for
1/N2, P  .21), and stage of disease (48% for stage I vs
9% for stage II/III, P  .71). Multivariate analysis showed
hat DFI was the only factor predictive of a poor prognosis
P  .0126).
iscussion
lso known as biphasic carcinomas, SCSGCs are rare tu-
ors, accounting for only 0.3% to 1.3% of all lung tu-
ors.6,8,12-14,18 In our experience they represent 1.4%.
owever, this percentage might be underestimated because
Figure 2. Overall survival according to tumor size.
igure 3. Overall survival according to the disease-free interval
DFI).
and Cardiovascular Surgery ● Volume 134, Number 3 621
t
c
t
a
c
h
W
a
f
m
c
a
c
m
i
m
t
a
a
i
d
s
o
w
p
p
fi
f
g
n
F
m
m
p
v
s
e
N
v
v
4
p
s
o
4
c
o
n
d
r
o
p
w
D
8
p
l
F
y
p
t
T
R
I
R
G
F
A
N
C
R
P
R
O
C
s terven
General Thoracic Surgery Venissac et al
6
G
TShe classification has changed over time. The 1981 WHO
lassification placed tumors with a giant cell component in
he group of large cell carcinomas and classed tumors with
spindle cell component in the group of squamous cell
arcinomas.3 Since the 1990s, this particular type of tumor
as received increased attention,7,9-13,15 and the most recent
HO classification groups them together.4,5
Histologic identification of these tumors remains difficult
nd requires examination of the resected surgical specimen
or several reasons.
First, SCSGCs are a highly heterogeneous group of tu-
ors. In addition to the sarcomatous component, we en-
ountered all other types of carcinomas in our series: 13
denocarcinomas, 13 squamous cell carcinomas, and 9 large
ell carcinomas. Moreover, 12 of the tumors contained a
ixture of 3 cell types.
Second, the most recent WHO classification, published
n 19994 and revised in 2004,5 requires a minimum sarco-
atoid component of 10% for positive diagnosis. In light of
his mixed multicellularity and the variations in the percent-
ges of the cell types, no preoperative technique permits
ccurate tumor diagnosis. Despite positive proof of cancer
n 19 of our patients, only 1 examination oriented the
iagnosis.
Finally, it is not known which component has a meta-
tatic potential. For example, the prevalent brain lesion in
ur M1 patient consisted solely of adenocarcinoma,
hereas the lung tumor had 3 components: 30% GCC, a
redominance of adenocarcinoma, and large cell carcinoma.
Our retrospective study also investigated the clinical and
rognostic behavior. Comparison of CT and pathologic
ndings19,20 revealed that an SCSGC should be suspected
or any peripheral necrotic lesion surrounded by ground-
lass attenuation. No study has been published in the inter-
ational literature on the use of F-18 FDG-PET scans.
able 2. Reported series for sarcomatoid lung cancer (spi
eference
No. of patients (period of
study [y]/centers)
shida and coworkers12 (1990) 8 (13/2) 
o and coworkers11 (1992) 14 (31/1) 
insberg and coworkers15 (1992) 16 (12/1) 
ishback and coworkers13 (1994) 57* (20/1) 
ttanoos and coworkers9 (1998) 46 (12/2) 
akajima and coworkers8 (1999) 37 (18/2) 
hang and coworkers16 (2001) 7† (10/1) 
ossi and coworkers6 (2003) 71‡ (17/2) 
elosi and coworkers7 (2003) 31 (11/2) 
aveglia and coworkers14 (2004) 20 (4/1) 
ur series (2006) 39 (15/1)
enters, Number of participating institutions; N, lymph node involvemen
urgical intervention. †Sixteen patients/7 patients treated with surgical inourteen patients in our study benefited from this imaging t
22 The Journal of Thoracic and Cardiovascular Surgery ● Septeodality, and all of their tumors showed intense enhance-
ent (standardized uptake value range, 16–26), a sign of
otential aggressiveness.21
The estimated 5-year survival rate in surgical series
aries between 13% and 21%.6-9,13-16 In our study 5-year
urvival was 33%. Even if the 3 postoperative deaths are
xcluded, the gain in survival was minimal (36% at 5 years).
aruke and colleagues22 reported the following 5-year sur-
ival rates for other types of NSCLCs after surgical inter-
ention: adenocarcinoma, 44%; squamous cell carcinoma,
3%; and large cell carcinoma, 38%. There are several
ossible explanations for this poor prognosis.
First, limited stages like IB or IIB had poorer 5-year
urvival rates than other types of cancer: 48% and 21% in
ur study and 62% and 40% for adenocarcinoma, 58% and
9% for squamous carcinoma, and 54% and 38% for large
ell carcinoma, respectively.22
Second, analysis of the natural history of the tumors in
ur patients revealed several interesting features: there were
o small T1 tumors, and 72% of our patients had N0
isease. Recurrences were mostly distant hematogeneous
ather than local lymph node metastases, and they were
bserved after a mean DFI of 4 months. All but 3 of our
atients died after a mean survival of 8 months. The DFI
as correlated with survival. Patients who relapsed with a
FI of less than 6 months had a 1-year survival rate of only
.3%, and all of them had died at 15 months. The 3 living
atients (with recurrences) all had a DFI of 6 months or
onger. The short mean DFI highlights the value of F-18
DG-PET scans for the detection of metastatic disease.
Third, the majority of events happened during the first
ear. The 1-year survival rate was only 40%. All of our
atients who passed the 2-year barrier are considered long-
erm survivors.
Although survival is somewhat better when complemen-
/giant cells)
5-y survival Median survival (mo) Prognostic factors
 8 
 13 
 14 
10% 10 Stage I, N0, size
15% 18 
  Stage I, N0
 5 
 19 Stage I
  Stage I
 8 Stage I, N0
33% 11 Size, DFI
, disease-free interval. *Seventy-eight patients/57 patients treated with
tion. ‡Seventy-five sarcomatoid cancers/71 spindle/giant cells cancers.ndle
t; DFIary treatments are administered, the difference is not sta-
mber 2007
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G
TSistically significant, perhaps because of several limitations:
etrospective study, small number of patients, or even the
iphasic features of SCSGC. Currently, all treatment strat-
gies and prognostic behaviors are based on monophasic
umor types.
In our experience the only prognostic factor was tumor
ize. Other authors have reported similar findings (Table
).6-9,11-15 Interestingly, our patient with M1 pT2 N0 dis-
ase had the longest survival (almost 180 months). She had
recurrences, 19 months (small bowel metastasis) and 30
onths (suprarenal metastasis) after lung surgery, respec-
ively. Each time, management consisted of surgical inter-
ention and adjuvant chemotherapy.
From a pragmatic point of view, the clinical features and
urvival data reflect tumor aggressiveness. Most of our
atients relapsed and died within 12 months of surgical
ntervention. Thereafter, the small-stage 5-year survival rate
as slightly shorter than that of other types of NSCLCs.
ong-term survival can sometimes be achieved by means of
ung resection combined with complete lymph node dissec-
ion. Complementary treatments had no significant value in
ur study, perhaps because of these tumors’ biphasic com-
osition. Induction or adjuvant chemotherapy should be
onsidered when the diagnosis is suspected preoperatively
ecause of the aggressive behavior of these tumors.
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